Immix Biopharma (NASDAQ: IMMX) priced a $125 million underwritten registered offering of common stock on September 29, 2026. The company sold 11,363,637 shares at a public offering price of $11.00 per share.

The gross proceeds are expected to be $125 million before deducting underwriting discounts, commissions, and offering expenses payable by the company. Immix intends to use the net proceeds to fund the development of its lead candidate, NXC-201, as well as for working capital and general corporate purposes. The offering is expected to close on or about September 30, 2026, subject to customary closing conditions.

Offering details

The transaction was structured as an underwritten registered offering pursuant to a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (SEC). J.P. Morgan served as the sole book-running manager for the deal.

Investor participation

The offering attracted participation from both new and existing institutional investors. Key participants included Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P., and Wellington Management. Other leading U.S. biotechnology institutional investors and mutual funds also participated in the round.

Strategic context

Immix Biopharma is a global leader in treating relapsed/refractory AL Amyloidosis, a disease where toxic light chains cause organ failure. Its lead candidate, NXC-201, is a sterically-optimized BCMA-targeted CAR-T cell therapy currently being evaluated in the U.S. multi-center NEXICART-2 study. The therapy has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the FDA, along with Orphan Drug Designation from both the FDA and the European Medicines Agency.

Pomerantz LLP has launched an investigation into Immix Biopharma, Inc. (NASDAQ: IMMX) regarding potential securities fraud, joining an earlier inquiry by Schall, Brown & Schwartz LLP. The probe focuses on whether the company and its officers misled investors about the identity of former Chief Medical Officer Richard Graydon, whose shares fell by $1.45, or 14.15%, to close at $8.80 on July 20, 2026, after media revealed he was actually Ronald L. Fischer, a fugitive arrested in July 2026.

Investigation Scope

The investigation examines disclosures surrounding Graydon’s appointment on March 30, 2026, and his termination on July 17, 2026. Immix Biopharma stated the departure was for "reasons unrelated to his activities at the company." However, U.S. Marshals Service reports later confirmed Graydon was Ronald L. Fischer, who had evaded capture for over 20 years after disappearing during a 2005 rape trial. Pomerantz LLP is assessing if this omission constituted a material breach of disclosure obligations.

Key Details

Legal Representation

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is leading the new investigation. The firm specializes in securities class actions and shareholder rights litigation. Investors who purchased Immix Biopharma stock between March 30, 2026, and July 20, 2026, are advised to contact Danielle Peyton at Pomerantz LLP to discuss their rights. This adds to the earlier investigation by Schall, Brown & Schwartz LLP, which also cited misleading statements regarding Graydon’s background.

What the Numbers Show

The 14.15% drop in share price underscores the market’s reaction to governance failures. The divergence between the company’s stated reason for termination and the actual criminal history of the executive highlights a significant transparency gap. This discrepancy suggests investors were deprived of material facts necessary to assess leadership risk, potentially violating securities laws.